1. Deacon HE, Freese JA, Sharp BL. 1994. Drug resistant falciparum malaria in the Eastern Transvaal. S Afr Med J. 84: 394-395.2. Freese JA, Sharp BL, et al. 1994. The in vitro
sensitivity of southern African isolates of Plasmodium falciparum to amodiaquine, chloroquine, mefloquine, quinine and sulfadoxine-pyrimethamine. S Afr J Sci. 90: 417-420.
3. Hansford CF. 1989. Chloroquine resistance in Plasmodium falciparum in KwaZulu 1983-1988. S Afr Med J. 76: 546-547.
4. Kruger P, Durrheim DN, Hansford CF. 1996. Increasing chloroquine
resistance - the Mpumalanga lowveld story 1990-1995. S Afr Med J. 86: 281-282.
5. Department of Health. 1995. Malaria: revised prophylaxis policy. S Afr Med J. 85: 126-127.
6. Warrell DA, Molyneux ME, Beales PF. 1990. Severe and complicated malaria. World Health Organization Division of Control of Tropical Diseases. Second edition. London: Royal Society of Tropical Medicine and
Hygiene.
7. Gilles HM. 1991. Management of severe and complicated malaria. A practical handbook. Geneva: World Health Organization.
8. Beadle C, Long GW, Weiss WR, et al
. 1994. Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet. 343: 564-567.
9. Abramowicz M. 1992. Drugs for parasitic infections.
Medical Letter. 34(865): 17-24.
10. Department of National Health and Population Development. 1994. Malaria in South Africa 1984-1993. Epidemiological Comments. 21(6): 110-117.
11. Luzzi GA, Peto TEA. 1993. Adverse effects of antimalarials: An update. Drug Safety. 8(4): 295-311.
12. Gelman CR, Rumack BH. 1995. DRUGDEX(R) Information System. Denver, Colorado: MICROMEDEX, Inc. 83.3.
13. World Health Organization. 1995. International travel and health guide: vaccination requirements and health advice. Geneva: World Health Organization.
14. Beards SC, Joynt GM, Lipman J. 1994. Haemodynamic
and oxygen transport response during exchange transfusion for severe falciparum malaria. Postgraduate Med J. 70: 801-804.
15. World Health Organization. 1990. Model prescribing information. Drugs used in
parasitic diseases. Geneva: World Health Organization: 41.
16. Nosten F, Price RN. 1995. New antimalarials: A risk-benefit analysis. Drug Safety. 12(4): 264-273.
17. Nosten F, Ter Kuile FO, et al
. 1993. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 341: 1054-1056.
18. World Health Organization. 1993. Artemisinin and its derivatives: use as antimalarials. WHO Drug Information.
7(3): 111-113.
19. Artemisinin. 1994. Proceedings of a meeting convened by the Wellcome Trust. Transactions of the Royal Society of Tropical Medicine and Hygiene. 88 (Supplement 1): S1-65.
20. Report of a WHO Scientific Group. 1990. Practical chemotherapy of malaria. World Health Organization Technical Report Series 805. Geneva: World Health Organization.
21. Zeneca. 1995. Primaquine phosphate tablets. Package insert. 13 October 1995.
22. Bruce-Chwatt LJ, Black RH, Canfield CJ, et al. 1986. Chemotherapy of Malaria. Revised second edition. Geneva: World
Health Organization.
23. Subramanian D, Moise KJ, White AC. 1992. Imported malaria in pregnancy: Report of four cases and review of management. Clin Inf Dis. 15: 408-13.
24. Vanhauwere B. 1995. Mefloquine. Post
Marketing Surveillance of Lariam in Pregnancy. F. Hoffman - La Roche, Basel, Switzerland. Fourth International Conference on Travel Medicine, Mexico, April 23-27 1995.
25. Chongsuphajaisiddhi T. 1988. Malaria in paediatric practice. In: Wernsdorfer McGregor eds. Malaria: principles and practice of malariology. Edinburgh: Churchill Livingstone: 889-912.
26. Schlagenhauf
P, Steffen R. 1994. Stand-by treatment of malaria in travellers: a review. J Trop Med Hyg. 97: 151-160.
